Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of fiscal year 2026, demonstrating steady progress across all markets and significant growth in its Innovative Medicines business.

Financial Highlights

Sun Pharma's gross sales for Q1 FY26 reached ₹137,861.00 million, marking a 10.1% increase year-over-year. The company's adjusted net profit rose by 5.7% to ₹29,961.00 million, excluding exceptional items. However, the reported net profit stood at ₹22,786.00 million, compared to ₹28,356.00 million in Q1 FY25, due to certain exceptional charges.

Market Performance

India Formulations

Sun Pharma continued to strengthen its leadership position in the Indian pharmaceutical market. Sales in India grew by 13.9% to ₹47,211.00 million, accounting for 34.2% of total consolidated sales. The company's market share increased from 8.0% to 8.3%, maintaining its No. 1 ranking. Sun Pharma launched 5 new products in the Indian market during the quarter.

US Formulations

US formulation sales reached $473.00 million, representing a 1.4% growth and contributing 29.3% to total consolidated sales.

Global Innovative Medicines

The company's Global Innovative Medicines business, previously known as Specialty business, showed impressive growth of 16.9%, reaching $311.00 million. This segment now accounts for 19.3% of Q1 FY26 sales, highlighting Sun Pharma's successful expansion into innovative drug development.

Emerging Markets and Rest of World

Emerging Markets formulation sales grew by 5.1% to $298.00 million, while Rest of World markets saw a significant increase of 15.5%, reaching $219.00 million.

R&D and Product Pipeline

Sun Pharma continued its focus on research and development, investing ₹9,029.00 million (6.5% of sales) in R&D during Q1 FY26. The company's innovative R&D pipeline includes six novel entities in clinical stages. In the US market, Sun Pharma has 542 approved ANDAs and 119 pending approvals, along with 57 approved NDAs and 13 pending approvals.

Launch of Leqselvi in the US

A significant milestone for Sun Pharma this quarter was the US launch of Leqselvi, a JAK inhibitor for severe alopecia areata. This launch not only expands the company's dermatology portfolio but also adds a new growth engine to its Innovative Medicines business.

Leadership Transition

Sun Pharma announced an important leadership change during its 33rd Annual General Meeting. Dilip Shanghvi, the company's founder, will transition from his role as Managing Director. Kirti Ganorkar, a long-standing member of Sun Pharma's leadership team, will take over as the new Managing Director, subject to shareholder approval.

Outlook

Dilip Shanghvi, Chairman and Managing Director, commented on the results: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance."

Looking ahead, Sun Pharma expects mid to high single-digit topline growth for FY26, with continued growth trajectory in its Global Specialty business. The company plans to maintain its R&D spend in the range of 6-8% of sales, with an increased focus on Specialty products.

As Sun Pharmaceutical Industries Limited continues to expand its global footprint and innovative product portfolio, it remains committed to delivering long-term value and touching more lives globally.

Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of the fiscal year 2026 (Q1FY26), demonstrating solid growth across its key markets and business segments.

Financial Highlights

• Gross sales reached ₹137,861.00 million, marking a 10.1% year-over-year growth
• Adjusted net profit increased by 5.7% to ₹29,961.00 million
• EBITDA rose by 19.2% to ₹43,017.00 million, with an EBITDA margin of 31.1%
• Profit before exceptional items and tax grew by 16.6% to ₹39,908.00 million

Market Performance

Sun Pharma continued to strengthen its position in various markets:

India Formulations

• Sales grew by 13.9% to ₹47,211.00 million, accounting for 34.2% of total consolidated sales
• Maintained No. 1 ranking with an increased market share of 8.3% in the Indian pharmaceutical market

US Formulations

• Sales reached US$473.00 million, up 1.4% and contributing 29.3% to total consolidated sales

Global Innovative Medicines

• This segment, formerly known as Specialty business, saw a significant growth of 16.9%, reaching US$311.00 million
• Accounted for 19.3% of Q1FY26 sales

Emerging Markets

• Formulation sales grew by 5.1% to US$298.00 million, representing 18.5% of total consolidated sales

Rest of World

• Formulation sales increased by 15.5% to US$219.00 million, contributing 13.6% to total consolidated sales

R&D and Product Pipeline

Sun Pharma continued its focus on research and development:

• R&D investments for Q1FY26 stood at ₹9,029.00 million, or 6.5% of sales
• The company's innovative R&D pipeline includes six novel entities in clinical stage
• In the US market:
  • 542 approved ANDAs and 119 pending approval
  • 57 approved NDAs and 13 awaiting approval
• During Q1, the company filed 2 ANDAs and received 1 ANDA approval

Management Commentary

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, commented on the results:

"Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Future Outlook

While specific future projections were not provided, the company's strong performance across various markets and its continued investment in R&D suggest a positive outlook. The growth in the Global Innovative Medicines segment and the recent launch of LEQSELVI in the US market are expected to be key drivers for future growth.

Sun Pharma's robust Q1FY26 results demonstrate the company's resilience and ability to grow across diverse markets. With its strong market position in India, expanding presence in the US and emerging markets, and focus on innovative medicines, Sun Pharma appears well-positioned for continued growth in the pharmaceutical industry.